You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Technology Transfer of the ATLAS and ATHENA Programs
SBC: Odyssey Science Innovations, LLC Topic: NIDADESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
TeamChip for High-throughput, Predictive Human Metabolism and Toxicology
SBC: Solidus Biosciences, Inc. Topic: NIEHSDESCRIPTION (provided by applicant): Solidus Biosciences, Inc. in partnership with Rensselaer Polytechnic Institute is proposing to address a critical need in chemical safety technology through its proprietary Transfected Enzyme and Metabolism Chip (or TeamChip) for high-throughput analysis of systematic drug candidate and chemical metabolism and toxicology. The TeamChip is being developed to mi ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
PROOF OF CONCEPT FOR ANTIMICROBIAL PROPERTIES OF LACRITIN IN VIVO
SBC: EYERX RESEARCH, INC. Topic: NEIDESCRIPTION (provided by applicant): Over the past sixty years, antibiotics have comprised a key component in both the treatment and prophylaxis of bacterial infections. Since that time the continuous development of new antibiotics has been necessary to limit toxicity, promote broader spectrum therapy, increase convenience of use, and decrease the time to clear the infection. Another driving force ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Topical Nanoparticles for CNV
SBC: NANOTRANS TECHNOLOGIES, INC. Topic: NEIDESCRIPTION (provided by applicant): Age Related Macular Degeneration (AMD) is the leading cause of blindness in adults over 50 years. Choroidal neovascularization (CNV), the pathologic creation of new blood vessels in the choroid layer of the eye, is a principal cause of blindness due to AMD. Current therapeutic management of AMD is far from optimal and requires repeated injections in the vitreou ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Rapid isolation of high-affinity human antibodies from large synthetic libraries
SBC: VYBION, INC. Topic: NIGMSDESCRIPTION (provided by applicant): With over 300 therapeutic proteins currently in various stages of clinical trials, the road to a healthier future will require new methods for producing safer and less expensive recombinant proteins. In particular, next generation therapeutics derived from monoclonal antibodies (e.g. Fab, scAb, scFv, immunotoxins, etc) show great clinical promise in treating a ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Sensor Network for Monitoring Real-world Arm Activity of Rehabilitation Patients
SBC: ACTIVE WAVE, INC. Topic: NICHDDESCRIPTION (provided by applicant): Evidence and theory indicate that laboratory measures of impairment and function do not predict how older adults actually function in daily life. Thomas Glass (1998), for example, reports marked differences between functional activities that community residents can do and do do in survey data from the MacArthur Studies of Successful Aging. Therefore, subst ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Neuroprotective therapy of stroke with HUCNC and simvastatin
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Identification and Characterization of Causative Genetic Biomarkers for Parkinson
SBC: POPULATION DIAGNOSTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): The goal of this project is to rapidly discover biomarkers for Parkinson's Disease (PD) by defining the spectrum of causal genetic loci for PD, not only for the purpose of accurate diagnosis and risk stratification but also in order to shed light on the underlying biology and pathways involved in PD pathogenesis for the purpose of future rational therapeutic de ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Hybernia Safety Catheter for Neuroprotection via Selective Hypothermia
SBC: Hybernia Medical, LLC Topic: NINDSDESCRIPTION (provided by applicant): Hypothermia is a powerful neuroprotective treatment for ischemic injury and is indicated for use in cardiopulmonary bypass, cardiac arrest, and neonatal hypoxia. However, current methods induce systemic hypothermia which requires significant time and has associated complications. Hybernia Medical, LLC is developing a device based on intellectual property assign ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice
SBC: Yecuris Corporation Topic: NCRRDESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health